Abstract:Cholangiocarcinomas (CCs) are primary hepatobiliary carcinomas of increasing importance and with major biological and therapeutic challenges. CCs may occur in any segment along the biliary tract and are presently also classified into two major categories according to their anatomic location. CCs arising from small bile duct and ductules to segmental large bile ducts are designated as intrahepatic or peripheral CC (ICC). Tumors originating from large bile ducts at the hilum (right or left hepatic bile duct or at their junction) or along the extrahepatic biliary tree are designated as extrahepatic bile duct carcinomas (BDC) or extrahepatic CC. Features of cholangiocyte differentiation characterize them; traditionally, they are thought to derive from the malignant transformation of bile duct epithelial cells and histologically classified as adenocarcinoma and rare variants. Recent data emphasized the significant degree of CCs’ heterogeneity in terms of their epidemiology and risk factors, pathological and molecular features, pathogenesis, and clinical behaviors and treatment and underlined the role of hepatic stem/progenitor cells as cell origin of a proportion of CC and their possible overlap with the major primary malignant tumor of the liver, namely hepatocellular carcinoma (HCC); precursor lesions and early lesions have been characterized underlining the existence of multistep carcinogenesis process. Overall, these data result in proposal of new histological or molecular classifications that could soon replace current anatomic-based classification and have major impact on establishment of prognosis and on development of novel target treatment approaches.

Histopathology and Molecular Pathogenesis of Cholangiocarcinoma